- Genprex, Inc. (GNPX) has been granted an exception by the Nasdaq Hearings Panel until **October 31, 2025**, to regain compliance with the **$1.00 Minimum Bid Price Requirement** and the **Minimum Stockholders’ Equity Requirement**.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:1]** **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:6]**  The company's stockholders' equity was **$1,391,195** as of June 30, 2025, which is below the required **$2.5 million**.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:6]** 
- To aid in regaining compliance, Genprex will effect a **one-for-fifty (1:50) reverse stock split** of its common stock, which will be effective at **12:01 a.m. Eastern Time on October 21, 2025**.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:2]** **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:6]**  Trading on a split-adjusted basis is anticipated to begin when the market opens on the same day.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:2]** 
- The company is currently enrolling patients in the Phase 2 expansion portion of its Acclaim-3 clinical trial for extensive stage small cell lung cancer (ES-SCLC), with interim analysis expected in the **second half of 2026**.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:4]** 
- Genprex plans to submit a request to the FDA to meet regarding IND-enabling studies for its GPX-002 diabetes gene therapy product by the end of **2025**.  **[1595248_0001437749-25-031210_gnpx20251001_8k.htm:5]**

Genprex (GNPX)